Diabetic Retinopathy Market Research Report - Forecast till 2027

Diabetic Retinopathy Market Research Report: Information by Type (Non-proliferative and Proliferative), Treatment (Anti-VEGF Drugs, Laser Photocoagulation, Vitreoretinal Surgery, Steroid Injection), by End User (Hospitals, Ambulatory Surgical Centers, Others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2027

ID: MRFR/MED/4336-HCR | February 2021 | Region: Global | 95 pages

Diabetic Retinopathy Market Speak to Analyst Request a Free Sample

Diabetic Retinopathy Market Overview

During the projection period, the diabetic retinopathy market is projected to expand at a CAGR of 11.9 percent during the forecast period. Diabetes retinopathy refers to a group of eye illnesses that affect diabetic people. High blood sugar levels cause the destruction of the blood vessels in the retina. This causes blood vessels to enlarge and leak, or the blood vessels might close, preventing blood from passing over. The market is driven by an increase in the prevalence of diabetes, a rise in the geriatric population, an increase in the incidence of diabetes-related blindness, and a greater focus on earlier detection to manage diseases. However, the shortage of qualified ophthalmologists and the long time it takes for medications to be approved are limiting this increase.

Patients' willingness to accept surgical treatments is predicted to increase as advanced technology, and minimally painful laser procedures with speedy recovery become available. Technological improvements in ophthalmic surgical and imaging devices will fuel diabetic retinopathy market expansion during the forecast years. Optical coherence tomography and other technologically advanced diagnostic technologies produce better cross-sectional images, allowing doctors to make better conclusions. Furthermore, surgical instruments are more precise, which improves surgery success rates. As a result, the availability of such improved ophthalmic devices and systems has made diagnostic and surgical operations easier, which has benefited the industry's growth.


The Global Diabetic Retinopathy Market has been segmented based on type, treatment, end-user, and region.

The market, based on type, has been segmented into non-proliferative and proliferative.

The market, based on treatment, has been segmented into anti-VEGF drugs, laser photocoagulation, vitreoretinal surgery, and steroid injection.

The market, based on end-user, has been segmented into hospitals, ambulatory surgical centers, and others.

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The diabetic retinopathy market in the Americas has further segmented into North America and Latin America, with the North American market divided into the US and Canada. The European diabetic retinopathy industry has been sub-divided into Western Europe and Eastern Europe. Western Europe has further the as Germany, France, UK, Italy, Spain, and the rest of Western Europe. The market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The diabetic retinopathy Industry in the Middle East & Africa has been divided into the Middle East and Africa.

Key Players

The key players in the Global Diabetic Retinopathy Market are F.Hoffmann-La Roche AG, Regeneron Pharmaceuticals, Inc., Alimera Sciences, Ampio Pharmaceuticals Inc., Aurolab, Allergan PLC, Abbott Laboratories, and others.

Regional Market Summary

Diabetic Retinopathy Global Market Share by Region, 2018 (%)  Diabetic Retinopathy Market

Source: World Health Organization (WHO)

The market in the Americas is expected to dominate the diabetic retinopathy market due to the presence of major established players in the region and increasing R&D expenses.

Europe is expected to hold the second-largest position in the diabetic retinopathy global market. This can be attributed to the presence of a well-established healthcare system and an increased prevalence of diabetes.

Asia-Pacific is expected to be the fastest-growing regional market owing to the increasing pool of population and increasing awareness about the products.

The diabetic retinopathy market in the Middle East & Africa is projected to account for the least share of the global market due to low disposable income in the region.

Recent Development 

Mar 2022 Pohang University of Science and Technology (POSTECH) researchers have developed smart LED contact lenses to prevent and treat diabetic retinopathy in its early stages. The wearable device irradiates the retina with a 120 W far-red/LED light. The researchers used diabetic animal models to test their revolutionary gadget and discovered that animals who wore the smart contact lenses for 15 minutes three times a week for a total of eight weeks did not develop diabetic retinopathy. The animals who did not use the lenses, on the other hand, developed retinopathic diseases.

Mar 2022 Baxter International has partnered with the artificial intelligence firm behind a diabetic retinopathy automated test for a relationship centered on the company's recently acquired Welch Allyn retinal camera. Digital Diagnostics, which received one of the first AI clearances from the FDA in 2018 with its IDx-DR system, will collaborate with Baxter to obtain an additional FDA green light that will allow the software to work with the RetinaVue 700 Imager. The businesses hope to receive the new clearance in 2023, and the AI arrangement will be exclusive in the United States but nonexclusive elsewhere. The FDA has previously approved IDx-DR for use with Topcon's NW400 retinal camera, situated in Tokyo.

Global Diabetic Retinopathy Market, by Type

  • Non-Proliferative

  • Proliferative

Global Diabetic Retinopathy Market, by Treatment

  • Anti- VEGF Drugs

  • Laser Photocoagulation

  • Vitreoretinal Surgery

  • Steroid Injection

Global Diabetic Retinopathy Market, by End User

  • Hospitals

  • Ambulatory Surgical Centers

  • Others

Global Diabetic Retinopathy Market, by Region

  • Americas

    • North America

      • US

      • Canada

    • Latin America

  • Europe

    • Western Europe

      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe

    • Eastern Europe

  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific

  • Middle East & Africa

    • Middle East

    • Africa

Intended Audience

  • Research and development (R&D) companies

  • Diabetic retinopathy manufacturing companies

  • Government research institutes

  • Academic institutes and universities

Report Scope:
Report Attribute/Metric Details
  Market Size   2018: USD 1,309.73 Billion
  CAGR   11.9% (2020-2025)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   type, treatment, end-user
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   F.Hoffmann-La Roche AG, Regeneron Pharmaceuticals, Inc., Alimera Sciences, Ampio Pharmaceuticals Inc., Aurolab, Allergan PLC, Abbott Laboratories
  Key Market Opportunities   lack of awareness about treatment
  Key Market Drivers

  • rising prevalence of diabetes
  • increasing prevalence of blindness due to diabetes
  • increasing geriatric population
  • increasing demand for diagnostic tests for the early diagnosis of diabetic retinopathy

  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    The valuation was USD 1,309.73 billion.

    The projected CAGR would be 11.9% during the forecast period of 2019 to 2025.

    The types included in the report are non-proliferative and proliferative.

    The treatments are vitreoretinal surgery, laser photocoagulation, anti-VEGF drugs, and steroid injection.

    Ambulatory surgical centers, hospitals, and others have been recorded as a part of the market report.